Evidence map›Paper›PMID 37363078›Full record

ArticleACS bio & med chem Au2023

Structure of the d-Cycloserine-Resistant Variant D322N of Alanine Racemase from

Cesira de Chiara, Gareth A Prosser, Roksana Ogrodowicz, Luiz P S de Carvalho

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS bio & med chem Au, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Cycloserine inhibits glutamate decarboxylase fromJournal of enzyme inhibition and medicinal chemistry · 2026
    Article
  2. Review
  3. Review
  4. A prototrophic suppressor of aJournal of bacteriology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Cesira de ChiaraMycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, London, NW1 1AT, United Kingdom.
Gareth A ProsserMycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, London, NW1 1AT, United Kingdom.
Roksana OgrodowiczStructural Biology Science Technology Platform, The Francis Crick Institute, London, NW1 1AT, United Kingdom.
Luiz P S de CarvalhoMycobacterial Metabolism and Antibiotic Research Laboratory, The Francis Crick Institute, London, NW1 1AT, United Kingdom.ORCID https://orcid.org/0000-0003-2875-4552
The Francis Crick Institute · GB

Funding

Wellcome Trust CC2000
6 · The paper itself

Abstract

Alanine racemase (Alr) is a pyridoxal 5'-phosphate-dependent enzyme that catalyzes the racemization of l-alanine to d-alanine. Alr is one of the two targets of the broad-spectrum antibiotic d-cycloserine (DCS), a structural analogue of d-alanine. Despite being an essential component of regimens used to treat multi- and extensively drug-resistant tuberculosis for almost seven decades, resistance to DCS has not been observed in patients. We previously demonstrated that DCS evades resistance due to an ultralow rate of emergence of mutations. Yet, we identified a single polymorphism (converting Asp322 to Asn) in the

Identifiers

PMID37363078
PMCPMC10288493
OpenAlexW4361001208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.